Cambridge Healthtech Institute’s 8th Annual
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Creating the Killer Combo
May 6-7, 2020
The development of bispecific antibodies is one of the hottest areas in biologic research at the moment and their advancement to preclinical and clinical development will determine what the future of this area will look like. The 8th Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference brings together leading researchers in this area to strategize on the safety and efficacy of new constructs, review the latest clinical results, and talk about expanding their use beyond oncology.
INNOVATION IN IMMUNO-ONCOLOGY BISPECIFIC ANTIBODIES
Current Status of Bispecifics Biologics and Combination Biologics Therapies
Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen
Ultraspecific Antibodies for Truly Specific Targeting of Solid Tumors
Jonny Finlay, PhD, CEO, UltraHuman Ltd.
REGN4018 Is a Mucin 16 Bispecific T Cell-Engaging Antibody for the Treatment of Ovarian Cancer
Alison Crawford, PhD, Senior Staff Scientist, Oncology & Angiogenesis, Regeneron Pharmaceuticals
Combinatorial Immune Checkpoint Blockade Using Clinical Stage Bispecific DART® Molecules MGD013 and MGD019
Alexey Berezhnoy, PhD, Scientist III, Cell Biology and Immunology, MacroGenics, Inc.
Development of 4-1BB:HER2
Ingmar Bruns, MD, PhD, Vice President, Clinical Development, Pieris Pharmaceuticals GmbH
Optimization of Preclinical Safety and Efficacy of Anti-HER2/CD3 TDB
Teemu Junttila, PhD, Principal Scientist, Translational Oncology, Genentech, Inc.
Development of CDX-527, a Novel Bispecific Immune Modulating Antibody Targeting PD-L1 and CD27
Joel Goldstein, PhD, Senior Director, R&D, Celldex Therapeutics
Blockade of Glycol-Immune Checkpoints (Siglecs) Using Bifunctional EAGLE for Cancer Immunotherapy
Li Peng, PhD, Senior Vice President, Research and Early Product Development, Palleon Pharmaceuticals
NOVEL MODALITIES AND NOVEL BIOLOGY: MAXIMIZING THE POTENTIAL OF BISPECIFIC TARGETING
KEYNOTE PRESENTATION: Bispecific Antibody Drug Development
Paul W.H.I. Parren, PhD, Executive Vice President, Head, R&D, Lava Therapeutics B.V.
Oncolytic Adenoviruses Armed with BiTes and Bikes
Ramon Alemany, PhD, Scientist, ProCure and Oncobell Programs, Catalan Institute of Oncology - IDIBELL
T Cells Redirected with Modular Biepitopic and Bispecific Antibody Mimic Receptors
Liu Rihe, PhD, Associate Professor, Chemical Biology and Medicinal Chemistry, Eschelman School of Pharmacy, University of North Carolina, Chapel Hill
Selective Blockade of the Immune Checkpoint CD47 Using Bi- and Multi-Specific Antibodies
Nicolas Fischer, PhD, CEO, Light Chain Bioscience, Novimmune SA
A Comprehensive Immunotherapy Strategy for Solid Cancers
Jogender Tushir-Singh, PhD, Assistant Professor, Biochemistry & Molecular Genetics, UVA Cancer Center, University of Virginia School of Medicine
* The program is subject to change without notice, due to unforeseen reason.